1Song Z, Zhou Z, Song M, et al. Betaine attenuated hepatic steatosis induced by long-term high carbohydrate diet feeding via increasing hepatic AMP-activated protein kinase activity. Gastroenterology, 2007, 132:A817.
2Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. AmJ Gastroenterol,2001,96:2711-2717.
3Miglio F, Rovati LC, Santoro A, et al. Efficacy and safety of oral betaine glucuronate in non alcoholic steatohepatitis. A doubleblind, randomized, parallel group, placebo-controlled prospective clinical study. Arzneimittelforschung,2000,50 : 722-727.
4Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr,2000,136: 734-738.
5Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-betal level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis. Aliment Pharmaeol Ther,2001, 15: 7667-]672.
6Stephen AH, Sigurd T, Paul H, et al. Vitamin E and Vitamin C Treatment Improves Fibrosis in Patients With Nonalcoholic Steatohepatitis. the American journal of gastroenterology, 2003,98 : 2485-2490.
7Nobili V, Manco M, Devito R, et al. Effect of vitamin E on aminotransferase levels and insulin resistance in children with nonalcoholic fatty liver disease. Alimentary Pharmacology Therapeutics,2006,24 : 1553-1561.
8Kaushal M, Batra Y, Gupta DS, et al. Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. Indian Journal of Gastroenterology, 2005,24 : 251-255.
9Letteron P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis leads to in vivo lipid peroxidation in mice. J, Hepatol, 1996,24 : 200-208.
2Day CP,James OF. Steatohepatitis:a tale of two "hits"? Gas- troenterology, 1998,114(4) :842-845.
3Shyangdan D,Clar C,Ghouri N,et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic re- view. Health Technol Assess,2011,15(38 ) : 100-110.
4Stein LL,Dong MH,Loomba R. Insulin sensitizers in nonalco- holic fatty liver disease and steatohepatitis:Current status. Adv Ther, 2009,26( 10 ) : 893-907.
5Martin CK,Redman LM,Zhang J,et al. Lorcaserin,a 5-HT (2C) receptor agonist,reduces body weight by decreasing ener- gy intake without influencing energy expenditure. J Clin En- doerinol Metab,2011,96(3) : 837-845.
6Fidler MC,Sanchez M,Raether B,et al. A one-year random- ized trial of lorcasefin for weight loss in obese and overweight adults:the BLOSSOM trial. J Clin Endocrinol Metab,2011,96 ( 10) : 3067-3077.
7O'Neil PM,Smith SR,Weissman NJ,et al. Randomized place- bo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus:tbe BLOOM-DM study. Obesity (Silver Spring), 2012,20(7): 1426-1436.
8Nelson A,Torres DM,Morgan AE,et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis:A randomized placebo-controlled trial. J Clin Gastroenterol, 2009,43 (10) : 990-994.
9Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD:Could they be a first-class ption? Adv Ther, 2008,25 ( 11 ) : 1141-1174.
10Yoshiji H,Kuriyama S,Yoshij J,et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis devel- opment in rats. Hepatology,2001,34(4 Pt 1 ) :745-750.
